Site search
2816 results for '' found
A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previo
A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previo
/research/clinical-trials/find-clinical-trials/a-phase-3-randomized-open-label-study-of-subcutaneous-nivolumab-relatlimab-fixed-dose-combination-versus-intravenous-nivolumab-relatlimab-fixed-dose-combination-in-participants-with-previo
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB [REGN2810], ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA [CSCC] OR BASAL CELL CARCINOMA [BCC] (NCT03889912)
A PHASE 1 STUDY OF PRE-OPERATIVE CEMIPLIMAB [REGN2810], ADMINISTERED INTRALESIONALLY, FOR PATIENTS WITH CUTANEOUS SQUAMOUS CELL CARCINOMA [CSCC] OR BASAL CELL CARCINOMA [BCC] (NCT03889912)
/research/clinical-trials/find-clinical-trials/a-phase-1-study-of-pre-operative-cemiplimab-regn2810-administered-intralesionally-for-patients-with-cutaneous-squamous-cell-carcinoma-cscc-or-basal-cell-carcinoma-bcc-nct03889912
A First-In-Human (FIH) Phase 1/2 Study To Assess Safety, Tolerability, And Preliminary Anti-Tumor Activity Of REGN7945, An Anti-CD38 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, In C
A First-In-Human (FIH) Phase 1/2 Study To Assess Safety, Tolerability, And Preliminary Anti-Tumor Activity Of REGN7945, An Anti-CD38 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, In C
/research/clinical-trials/find-clinical-trials/a-first-in-human-fih-phase-1-2-study-to-assess-safety-tolerability-and-preliminary-anti-tumor-activity-of-regn7945-an-anti-cd38-x-anti-cd28-costimulatory-bispecific-monoclonal-antibody-in-c
Reducing the frequency of outpatient review in people with cystic fibrosis on high-efficacy modulator therapy – a non-inferiority, randomised controlled trial (REFORM) (ACTRN12624000696594)
Reducing the frequency of outpatient review in people with cystic fibrosis on high-efficacy modulator therapy – a non-inferiority, randomised controlled trial (REFORM) (ACTRN12624000696594)
/research/clinical-trials/find-clinical-trials/reducing-the-frequency-of-outpatient-review-in-people-with-cystic-fibrosis-on-high-efficacy-modulator-therapy-a-non-inferiority-randomised-controlled-trial-reform-actrn12624000696594
A Dose Adjusted, Open Label, Multi-Centre Study to Determine the Safety, Tolerability and Pharmacokinetics of STC3141 Administered as an Infusion forup to 72 hours in Subjects with Sepsis and Nor
A Dose Adjusted, Open Label, Multi-Centre Study to Determine the Safety, Tolerability and Pharmacokinetics of STC3141 Administered as an Infusion forup to 72 hours in Subjects with Sepsis and Nor
/research/clinical-trials/find-clinical-trials/a-dose-adjusted-open-label-multi-centre-study-to-determine-the-safety-tolerability-and-pharmacokinetics-of-stc3141-administered-as-an-infusion-forup-to-72-hours-in-subjects-with-sepsis-and-nor
REDEEM: A randomised controlled trial of VV ECMO to de-sedate, extubate, and mobilise in hypoxic respiratory failure. (NCT05562505)
REDEEM: A randomised controlled trial of VV ECMO to de-sedate, extubate, and mobilise in hypoxic respiratory failure. (NCT05562505)
/research/clinical-trials/find-clinical-trials/redeem-a-randomised-controlled-trial-of-vv-ecmo-to-de-sedate-extubate-and-mobilise-in-hypoxic-respiratory-failure-nct05562505
Recovery-focused Community support to Avoid readmissions and improve participation after Stroke (ACTRN12618001468213)
Recovery-focused Community support to Avoid readmissions and improve participation after Stroke (ACTRN12618001468213)
/research/clinical-trials/find-clinical-trials/recovery-focused-community-support-to-avoid-readmissions-and-improve-participation-after-stroke-actrn12618001468213
A Randomised Clinical Trial of a digital Self-Management package for people with Interstitial Lung Disease (ACTRN12623001133628)
A Randomised Clinical Trial of a digital Self-Management package for people with Interstitial Lung Disease (ACTRN12623001133628)
/research/clinical-trials/find-clinical-trials/a-randomised-clinical-trial-of-a-digital-self-management-package-for-people-with-interstitial-lung-disease-actrn12623001133628
RATIONALISE - Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension (TRU-RLS-21) (ACTRN12622000359730)
RATIONALISE - Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension (TRU-RLS-21) (ACTRN12622000359730)
/research/clinical-trials/find-clinical-trials/rationalise-role-of-antibiotic-therapy-or-immunoglobulin-on-infections-in-haematology-immunoglobulin-stopping-or-extension-tru-rls-21-actrn12622000359730
A multi-centre, pRospective, safety and efficacy evaluation study on Automated external defibrillation in PatIents with CellAED (ACTRN12621000258853)
A multi-centre, pRospective, safety and efficacy evaluation study on Automated external defibrillation in PatIents with CellAED (ACTRN12621000258853)
/research/clinical-trials/find-clinical-trials/a-multi-centre-prospective-safety-and-efficacy-evaluation-study-on-automated-external-defibrillation-in-patients-with-cellaed-actrn12621000258853